Combination use of irinotecan and gefitinib showed synergistic antitumor effects on HepG2 xenograft models.

<p>A to D, Nude mice bearing established HepG2 tumors were treated with irinotecan at 1 mg/kg every 2 days by intraperitoneal injections, and/or gefitinib at 100 mg/kg daily by intragastric administration for 31 days. A, Average body weights were shown as the mean ± SEM. B, Morphology and weight of tumor were expressed as the mean ± SEM. **P < 0.01 versus vehicle treated controls (n = 6/group). C, Tumor volume and relative tumor volume were expressed as the mean ± SEM. D, Protein were extracted from tumor tissues from mice in 4 groups and cleaved-PARP, cleaved caspase-3, cleaved caspase-8 and Rad51 were determined by Western blot. E, model picture to summarize the motif.